Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week phase 2b randomized double-blind dose-ranging study of PF-06882961 (danuglipron) in adults with obesity
jRCT2031200422Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of danuglipron in obesity (9 arms), sponsored by Pfizer. Primary endpoint: Percent change from baseline in body weight at Week 26. Started Feb 2021; status: completed.
02
Drugs
danuglipron
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT2031200422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200422.